The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood. Vascular endothelial growth factor (VEGF)-A plays a principle role in tumor progression and angiogenesis; however, its role in tumor-associated lymphangiogenesis and lymphatic metastasis has remained unclear. We created transgenic mice that overexpress VEGF-A and green fluorescent protein specifically in the skin, and subjected them to a standard chemically-induced skin carcinogenesis regimen. We found that VEGF-A not only strongly promotes multistep skin carcinogenesis, but also induces active proliferation of VEGF receptor-2–expressing tumor-associated lymphatic vessels as well as tumor metastasis to the sentinel and distant lymph nodes. The lymphangiogenic activity of VEGF-A–expressing tumor cells was maintained within metastasis-containing lymph nodes. The most surprising finding of our study was that even before metastasizing, VEGF-A–overexpressing primary tumors induced sentinel lymph node lymphangiogenesis. This suggests that primary tumors might begin preparing their future metastatic site by producing lymphangiogenic factors that mediate their efficient transport to sentinel lymph nodes. This newly identified mechanism of inducing lymph node lymphangiogenesis likely contributes to tumor metastasis, and therefore, represents a new therapeutic target for advanced cancer and/or for the prevention of metastasis.
Skip Nav Destination
Article navigation
4 April 2005
Article|
April 04 2005
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
Satoshi Hirakawa,
Satoshi Hirakawa
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Search for other works by this author on:
Shohta Kodama,
Shohta Kodama
2Department of Immunobiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Search for other works by this author on:
Rainer Kunstfeld,
Rainer Kunstfeld
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Search for other works by this author on:
Kentaro Kajiya,
Kentaro Kajiya
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
3Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Lawrence F. Brown,
Lawrence F. Brown
4Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
Search for other works by this author on:
Michael Detmar
Michael Detmar
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
3Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Satoshi Hirakawa
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Shohta Kodama
2Department of Immunobiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Rainer Kunstfeld
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
Kentaro Kajiya
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
3Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8093 Zurich, Switzerland
Lawrence F. Brown
4Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
Michael Detmar
1Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129
3Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8093 Zurich, Switzerland
CORRESPONDENCE Michael Detmar: [email protected]
Abbreviations used: K14, keratin 14; BrdU, 5-bromo-2′deoxyuridine; DMBA, 7,12-dimethylbenzanthracene; LEC, lymphatic endothelial cell; LYVE-1, lymphatic vessel endothelial hyaluronan receptor 1; SCC, squamous cell carcinoma; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
Received:
September 14 2004
Accepted:
January 31 2005
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2005
J Exp Med (2005) 201 (7): 1089–1099.
Article history
Received:
September 14 2004
Accepted:
January 31 2005
Citation
Satoshi Hirakawa, Shohta Kodama, Rainer Kunstfeld, Kentaro Kajiya, Lawrence F. Brown, Michael Detmar; VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis . J Exp Med 4 April 2005; 201 (7): 1089–1099. doi: https://doi.org/10.1084/jem.20041896
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement